Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

[Preprint] Lab study shows Omicron infection enhances neutralizing immunity against the Delta variant.

11 Jan, 2022 | 01:29h | UTC

Omicron infection enhances neutralizing immunity against the Delta variant – medRxiv

 

Study shows Covid-19 vaccination is associated with a smaller reduction in transmission of the delta variant compared with the alpha variant.

11 Jan, 2022 | 01:31h | UTC

Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants – New England Journal of Medicine

 

Commentary on Twitter

 

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.

11 Jan, 2022 | 01:26h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid Advisory for Ontario

 

Commentary on Twitter

 

M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome.

11 Jan, 2022 | 01:28h | UTC

Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis – Brain, Behavior, and Immunity

 

Covid-19: An urgent call for global “vaccines-plus” action.

11 Jan, 2022 | 01:22h | UTC

Covid-19: An urgent call for global “vaccines-plus” action – The BMJ

 

CDC Report: COVID-19 vaccine safety in children aged 5–11 Years.

9 Jan, 2022 | 01:09h | UTC

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: COVID-19 vaccine appears safe in children aged 5–11 Years – News Medical

 

Commentary on Twitter

 

New CDC Guidance shortens isolation and quarantine period for Covid-19; patients that tested positive should isolate for 5 days and, if asymptomatic after this period, can leave isolation if they can continue to mask for 5 days to minimize the risk of infecting others.

9 Jan, 2022 | 01:13h | UTC

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population – Centers for Disease Control and Prevention

See also: Quarantine and Isolation – Centers for Disease Control and Prevention

Commentaries:

Facing criticism, CDC updates Covid-19 isolation recommendations with guidance on testing – CNN

CDC posts rationale for shorter isolation, quarantine – Associated Press

Covid-19: CDC shortens isolation period as US cases hit record high – The BMJ

Shortened CDC COVID isolation guide draws sharply mixed reviews – CIDRAP

New CDC isolation guidelines raise concerns among health experts – NPR

CDC Reduces Recommended Isolation Time for People With COVID-19 – HealthDay

COVID isolation and quarantine period for general population shortened by CDC – News Medical

CDC shortens recommended Covid-19 isolation and quarantine time – CNN

CDC cuts the recommended isolation and quarantine periods for coronavirus infections – NPR

US officials recommend shorter COVID isolation, quarantine – Associated Press

See new recommendations from other countries:

France cuts isolation times and plans crackdown on unvaccinated amid record surge in Covid cases – CNN

Covid: Self-isolation cut from 10 days to seven with negative tests – BBC

 

Omicron’s feeble attack on the lungs could make it less dangerous.

11 Jan, 2022 | 01:23h | UTC

Omicron’s feeble attack on the lungs could make it less dangerous – Nature

 

CDC Study: A test to stay strategy (allowing close contacts with masked COVID-19 exposures to remain in school) was very efficacious in preventing further school spread and allowed children to stay in the classroom as an alternative to home quarantine.

9 Jan, 2022 | 01:07h | UTC

Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools — Lake County, Illinois, August 9–October 29, 2021 – CDC Morbidity and Mortality Weekly Report

Related CDC Study: Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021 – CDC Morbidity and Mortality Weekly Report

Related CDC Guidance:

What You Should Know About COVID-19 Testing in Schools – Centers for Disease Control and Prevention

Science Brief: Transmission of SARS-CoV-2 in K-12 Schools and Early Care and Education Programs – Updated – Centers for Disease Control and Prevention

Commentary: ‘Test-to-stay’ works to keep students in school safely, CDC director says – CNN

Related:

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

 

Commentary on Twitter

 

Diagnostics for COVID-19: moving from pandemic response to control.

8 Jan, 2022 | 23:33h | UTC

Diagnostics for COVID-19: moving from pandemic response to control – The Lancet

 

Commentary on Twitter

 

[Preprint] Among individuals with prior SARS-CoV-2 infection in Brazil, vaccine effectiveness against hospitalization or death after vaccine series completion was 81.3% for CoronaVac, 89.9% for AstraZeneca, 57.7% for J&J, and 89.7% for Pfizer.

8 Jan, 2022 | 23:26h | UTC

Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among – medRxiv

 

[In Portuguese] Commentary from one of the authors on Twitter (thread – click for more)

 

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

9 Jan, 2022 | 01:05h | UTC

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv

Commentary: An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older – News Medical

Note: this study is an updated analysis of a recent study published in Nature Medicine; see below:

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

 

Compared with previous waves, the Omicron wave in South Africa was associated with fewer hospitalizations and decreased severity and mortality.

8 Jan, 2022 | 23:23h | UTC

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves – JAMA

 

[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

8 Jan, 2022 | 23:28h | UTC

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

 

[Preprint] Study showed reduced clinical severity of Covid-19 patients admitted to hospitals in Gauteng, South Africa, during the Omicron-dominant fourth wave – “any combination of a less-virulent virus, comorbidities, high immunity from prior infection(s) or vaccination may be important contributors to this clinical presentation”.

8 Jan, 2022 | 23:24h | UTC

Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave – SSRN/Preprints with The Lancet

Commentary: SARS-CoV-2 omicron variant may be less severe than the delta variant – News Medical

 

New AAP Guidance recommends routine HIV screening to all youth 15 years or older.

8 Jan, 2022 | 23:13h | UTC

Adolescents and Young Adults: The Pediatrician’s Role in HIV Testing and Pre- and Postexposure HIV Prophylaxis – Pediatrics

Commentary: Pediatricians Can Play Key Role in HIV Testing, Prophylaxis – HealthDay

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

8 Jan, 2022 | 23:07h | UTC

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London

 

Commentaries on Twitter

 

AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.

17 Dec, 2021 | 09:57h | UTC

Interim Guidance on Supporting the Emotional and Behavioral Health Needs of Children, Adolescents, and Families During the COVID-19 Pandemic – American Academy of Pediatrics

Commentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 

CDC advisors recommend mRNA COVID vaccines over J&J.

17 Dec, 2021 | 09:46h | UTC

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

 

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.

17 Dec, 2021 | 09:48h | UTC

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.